View Older Stories View More Recent Stories

Jul 24, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 23, 2025 04:30PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 23, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 18, 2025 04:34PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 18, 2025 04:31PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 10, 2025 06:30AM Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD
Jun 25, 2025 05:37PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jun 25, 2025 05:32PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
Jun 24, 2025 05:03PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jun 24, 2025 04:59PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
Jun 11, 2025 08:41AM Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Jun 10, 2025 08:00AM Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
Jun 6, 2025 06:30AM Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
May 29, 2025 07:30AM Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
May 21, 2025 08:00AM Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025
May 17, 2025 08:00AM Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
May 14, 2025 04:15PM Form 13F-HR Atlas Venture Life Scien For: Mar 31
May 9, 2025 06:00AM Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025
May 8, 2025 11:01AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 8, 2025 10:58AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 8, 2025 10:53AM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 8, 2025 10:48AM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 6, 2025 05:15PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
May 6, 2025 05:11PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Apr 30, 2025 04:29PM Form SCHEDULE 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
Apr 28, 2025 04:35PM Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
Apr 23, 2025 08:00AM Rectify Pharma to Share Preclinical Data Highlighting Progress in Hepatobiliary Program at EASL 2025
Apr 17, 2025 11:00AM Scion Life Sciences Expands Team with Appointment of Three Venture Partners
Apr 15, 2025 07:00AM Remix Therapeutics Appoints Linda C. Bain to Board of Directors
Apr 7, 2025 09:00AM Rectify Pharma Announces Publication of BSEP Transporter Biophysical Characterization in Communications Biology
Apr 7, 2025 02:00AM Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director
Mar 3, 2025 09:00AM Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer
Feb 19, 2025 09:16AM NAYA Biosciences (NAYA) nominates new Board members
Feb 19, 2025 09:15AM NAYA Biosciences Announces Nomination of New Board Members
Feb 18, 2025 04:59PM Form SCHEDULE 13D Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Feb 18, 2025 03:30AM LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
Feb 11, 2025 12:12PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 11, 2025 12:08PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 11, 2025 12:02PM Form 13F-NT Atlas Venture Fund VIII, For: Dec 31
Feb 11, 2025 11:59AM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Feb 10, 2025 04:05PM Form 4 Sionna Therapeutics, For: Feb 10 Filed by: Atlas Venture Associates Opportunity II, LLC
Feb 6, 2025 09:13PM Form 3 Sionna Therapeutics, For: Feb 06 Filed by: Atlas Venture Fund XI, L.P.
Feb 6, 2025 04:59PM Form 13F-HR Atlas Venture Life Scien For: Dec 31
Feb 6, 2025 09:00AM Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates
Feb 5, 2025 04:06PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 4, 2025 05:14PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 3, 2025 04:28PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jan 29, 2025 08:00AM Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment
Jan 15, 2025 09:00AM Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
Jan 9, 2025 08:15AM Lifordi Immunotherapeutics Appoints Matthew W. McClure, M.D., as Chief Medical Officer
View More Recent Stories View Older Stories